Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year Low Following Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low on Monday after Wedbush lowered their price target on the stock from $32.00 to $29.00. Wedbush currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $20.17 and last traded at $20.17, with a volume of 657271 shares […]

Related Keywords

Cedric Francois ,Alec Machiels ,Raymond James ,Citigroup ,Hennion Walsh Asset Management Inc ,News Ratings For Apellis Pharmaceuticals Daily ,Lisanti Capital Growth ,Wells Fargo Company ,Macquarie Group Ltd ,Goldman Sachs Group ,Apellis Pharmaceuticals Inc ,Jpmorgan Chase Co ,Institutional Trading Of Apellis Pharmaceuticals ,Apellis Pharmaceuticals Stock Performance ,Nasdaq ,Advisors Inc ,Securities Exchange Commission ,Apellis Pharmaceuticals ,Get Free Report ,Director Alec Machiels ,Exchange Commission ,Walsh Asset Management ,Mahoney Asset Management ,Capital Growth ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Stocks ,Technicals ,